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REVIEW
Guidelines for processing and reporting of prostatic
needle biopsies
Th H van der Kwast, C Lopes, C Santonja, C-G Pihl, I Neetens, P Martikainen,
S Di Lollo, L Bubendorf, R F Hoedemaeker, members of the pathology committee of
the European Randomised Study of Screening for Prostate Cancer (ERSPC)
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J Clin Pathol 2003;56:336–340
The reported detection rate of prostate cancer, lesions
suspicious for cancer, and prostatic intraepithelial
neoplasia (PIN) in needle biopsies is highly variable. In
part, technical factors, including the quality of the
biopsies, the tissue processing, and histopathological
reporting, may account for these differences. It has been
thought that standardisation of tissue processing might
reduce the observed variations in detection rate.
Consensus among the members of the pathology
committee of the European Randomised study of
Screening for Prostate Cancer (ERSPC) concerning the
optimal methodology of tissue embedding resulting in
guidelines for prostatic needle biopsy processing was
reached. The adoption of an unequivocal and uniform
way of reporting lesions encountered in prostatic needle
biopsies is considered helpful for decision taking by the
clinician. The definition of parameters for quality control
of prostatic needle biopsy diagnostics will further
facilitate clinical epidemiological multicentre studies of
prostate cancer.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Prostatic needle biopsies are an essential toolin the diagnosis of prostate cancer becausethey allow its definite diagnosis. Raised
serum prostate specific antigen (PSA) concentra-
tions prompt the clinician to perform transrectal
or, less frequently, transperineal needle biopsies,
which results into the discovery of many clinically
non-manifest prostate cancers. A considerable
downstaging and downgrading of prostate cancer
has been achieved by this procedure.1 2 In the lit-
erature, much attention has been paid to the his-
tological criteria of the most commonly accepted
precursor lesion of prostate cancer—prostatic
intraepithelial neoplasia (PIN)—and for “look a
likes” of prostate cancer, such as postatrophic
hyperplasia. In addition,much attention has been
paid to the accuracy of prostate cancer grading in
needle biopsies.3 Furthermore, small lesions
resembling adenocarcinoma, which are occasion-
ally encountered in prostatic needle biopsies and
cause diagnostic difficulties, have been
described.4
A few papers have looked at the quality of pro-
static needle biopsy tissue processing.5 6 It was
shown that an optimal processing procedure,
leading to a maximum amount of tissue being
examined by the pathologist, could increase the
sensitivity for the detection of prostate cancer.
These kinds of studies could provide a sound basis
for a set of guidelines on the tissue processing of
prostatic needle biopsies.
“Raised serum prostate specific antigen
concentrations prompt the clinician to
perform transrectal or, less frequently,
transperineal needle biopsies, which results
into the discovery of many clinically
non-manifest prostate cancers”
The European Randomised Study of Screening
for Prostate Cancer (ERSPC) is a collaboration of
eight European centres that investigate the
impact of screening for prostate cancer on
mortality and quality of life of men between 50
and 75 years of age. These men are randomised
into screening and non-screening arms.7 Screen-
ing consists of a systematic sextant needle biopsy
procedure in men with raised PSA values. The
pathology committee of the ERSPC was installed
to obtain uniformity in histopathological report-
ing of the prostatic needle biopsy specimens and
to enhance the quality of tissue processing. In a
small side study within the ERSPC, it was noted
that a substantial difference in the quality of pro-
static needle biopsies was associated with dis-
crepant detection rates among different partici-
pating centres of the ERSPC. Here, we report on
the recommendations of the pathology com-
mittee of the ERSPCwith regard to the processing
and the reporting of prostatic needle biopsies.
UROLOGICAL WORK UP, REVIEW
POLICY, AND ADMINISTRATIVE
PROCEDURES
In a small side study, the slides of prostatic needle
biopsies of 10 randomly selected participants of
the ERSPC study from five centres were examined
for their adequacy and their length. Needle biop-
sies were considered adequate if at least a single
prostatic gland was present and needle biopsies
that merely contained stromal tissue were consid-
ered inadequate. A considerable variation in the
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length of the biopsy sets was noted among different centres.
The number of adequate needle biopsies for each case also dif-
fered. The average total amount of prostatic tissue for each
participant and the detection rate of prostate cancer in the
individual centres correlated well (fig 1). It was noted that
many biopsies were fragmented, which impeded a proper
evaluation. In line with these data, Iczkowski et al demon-
strated that the length of the biopsy correlates with the pros-
tate cancer detection rate.8 Although these observations stress
the importance of adequate tissue processing by the pathology
laboratory, these data also show that the biopsy technique and
the skill of the urologist can greatly influence the diagnostic
outcome. Therefore, it is strongly recommended that the uro-
logical work up and the biopsy procedure should be performed
by a limited number of experienced specialists in each screen-
ing centre.
A learning curve may exist for pathologists who report pro-
static needle biopsies. Therefore, it was initially agreed within
the ERSPC that each ERSPC centre would institute a
“reference” pathologist who is responsible for prostate needle
biopsy diagnostics. Centres with a large, multistaff pathology
laboratory have adopted the policy that the biopsies would be
examined by the general pathologists, but that cases with
malignancy, suspect lesions, or PIN would be reviewed by a
reference pathologist. Data from one of the ERSPC centres
revealed that after the review of approximately 1000 cancer
cases, the diagnosis of prostate cancer was reversed by the ref-
erence pathologist in five cases. In two cases of a misdiagnosis
of prostate cancer an exchange of material during the report-
ing had been made and in the remaining three cases
postatrophic hyperplasia in needle biopsies had been mis-
taken for prostate cancer. In one additional case, where a
prostate cancer was not found in the corresponding radical
prostatectomy specimen, an exchange of one of the six
biopsies between two different participants was eventually
confirmed by molecular pathological analysis. Five of these six
serious mistakes were avoided by the institution of the refer-
ence pathologist.
An obvious and simple measure to avoid mixing of biopsies
by the pathologist is to deliver needle biopsies of one patient
each on a separate plateau. For the cases of misdiagnoses by
misinterpretation, it is likely that continued training of
general pathologists by the reference pathologist and a low
threshold consultation function of the reference pathologist
can largely avoid false positive diagnoses.
GUIDELINES FOR ADEQUATE PROSTATIC TISSUE
PROCESSING
The following processing issues have proved to be important
for achieving a maximum amount of evaluable prostatic tissue
in the prostatic needle biopsies.
The number of biopsies embedded in one cassette
Urologists want to know at which site the prostate cancer is
located. This information may help to decide whether a
unilateral nerve sparing prostatectomy is possible. In cases of
lesions suspect for adenocarcinoma, it is important to know
their localisation for site specific repeat biopsy. It is much
preferable that each biopsy core should be embedded
separately, but the consensus minimum requirement of the
pathology committee of the ERSPC is that biopsies obtained
from one side of the prostate should be embedded separately
from those obtained from the other side. It is noted that sepa-
rate embedding of each biopsy core was not explicitly recom-
mended by the World Health Organisation pathology com-
mittee during the second international consultation9 or the
Royal College of Pathologists UK.10 Obviously, if there are
additional biopsies taken from a suspect lesion based on dig-
ital rectal examination or transrectal ultrasound they should
always be embedded separately.
The procedure of embedding of needle biopsies into
paraffin wax
Because needle biopsies tend to become curved after fixation,
flat embedding of the biopsy cores can enhance the amount of
tissue that is examined by the pathologist. Flattening of
biopsy cores can be achieved by stretching the needle biopsies
between two nylon meshes or by wrapping them in a piece of
paper.6 11 This can be done even after initial formalin fixation.
If multiple cores are embedded in one cassette, it is necessary
to take care that all are separated from each other. This will
prevent multiple entangled biopsies from being represented
only partially in the mounted sections. An advantage of sepa-
rate embedding of individual cores is that additional handling
is avoided, reducing a source of damage to the biopsies.
Improvement for needle biopsy sectioning
Easy visualisation of the core biopsy in the paraffin wax
greatly helps the cutting of sections without losing too much
prostatic tissue. In some laboratories it is common practice to
add eosin or another colour solution to the biopsies before
embedding to allow easy visualisation for the histotechnician
during sectioning of the paraffin wax block.
The number of sections from each biopsy core (levels of
sectioning)
Earlier reports3 11 12 have shown that so as not to miss small
foci of adenocarcinoma it is mandatory to cut several sections
of each biopsy core at different levels. Cutting biopsy cores at
different levels may allow a definite diagnosis of adenocarci-
noma when a small focus is found at a single level. Because it
was not reported whether biopsy cores were flattened before
embedding the recommendation of these studies to cut three
different levels may probably not be necessary in the case of
adequately flattened cores. Therefore, within the pathology
committee of the ERSPC it is recommended that subsequent
sections of a core at two different levels should be sufficient.
Ribbons between the two levels can be stored for cases where
additional histological slides or immunohistochemistry are
required.
Figure 1 The relation between the cumulative length of sextant
biopsies and the detection rate of prostate cancer in men who
underwent sextant needle biopsy. Each letter in the figure represents
a separate centre participating in the ERSPC
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Preservation of paraffin wax ribbons for additional
staining
Some centres preserve paraffin wax ribbons of sectioned pro-
static needle biopsies for the eventuality of additional
stainings. Others perform two levels of sectioning in a way
that saves approximately half of the tissue for additional sec-
tioning if it is required. The use of a histo-collimator, a
commercially available optical instrument for alignment of
the block face to the cutting plane of the microtome, avoids
tissue waste during recutting a previously sectioned paraffin
wax block.
Most often, additional mounted sections will be requested if
at the original levels a lesion suspect for adenocarcinoma is
observed.
Immunohistochemistry and other stainings
In general, immunohistochemistry for basal cell specific kera-
tin will be used to distinguish PIN, atrophy, or adenosis from
adenocarcinoma.3 However, it should be stressed that the
absence of basal cell staining may not be considered to be
definite proof of malignancy.13 Some centres consider it help-
ful to perform mucin stainings14 or Van Gieson stainings on
suspect lesions to establish a definite diagnosis of adenocarci-
noma.
GUIDELINES FOR UNIFORM REPORTING OF
PROSTATE LESIONS
In screened populations we generally deal with men without
manifest prostate cancer. These men frequently lack signs of
prostate cancer at digital rectal examination or transrectal
ultrasonography. Increased PSA values, digital rectal exami-
nations, or transurethral ultrasonography lack specificity for
the detection of prostate cancer. A well known example of a
false positive outcome of clinical examination is granuloma-
tous prostatitis leading both to a suspect lesion at digital rec-
tal examination and very high concentrations of PSA.15 To
avoid bias, we and others3 recommend that pathologists read
the needle biopsies blindly; that is, without knowledge of the
outcome of previous clinical examinations.
Reporting of the histopathology of prostatic needle biopsies
in a screening setting should be as unequivocal and concise as
possible. This means that the nomenclature of prostatic
lesions in pathology reports should be uniform.10 Terms such
as “atypical glands”, “glandular atypia”, “probably malig-
nant”, “but benign not excluded” should be avoided, because
it is not clear to the urologist what further action should be
taken. The nomenclature of lesions that are “suspicious but
not diagnostic for prostate cancer” has been much
debated.4 16 17
“Reporting of the histopathology of prostatic needle
biopsies in a screening setting should be as
unequivocal and concise as possible”
The number of biopsies and the length of each needle biopsy
should be given in the gross description (macroscopy) section
of the pathology report.10 Inadequacy of any prostatic needle
biopsies should be stated in the pathology report. An
inadequate prostatic core biopsy is defined as a core lacking
glandular structures. For review in cases of a later occurring
carcinoma, it is important to know to what extent the original
sextant core biopsies were diagnostically adequate. Particu-
larly when one or more separate core biopsies are taken from
an area clinically suspect for malignancy, it is of importance to
mention this inadequacy in the report. If seminal vesicle tissue
is present in any of the biopsies this should be stated in the
report.
The following terms are recommended by the pathology
committee of the ERSPC because they seem to have proved
their value and consistency in the past several years.
• Benign, no abnormality. This includes fibromuscular and
glandular hyperplasia, in addition to foci of chronic
(lymphocytic) inflammation. It has been noted that
distinctions between the above entities are of limited clini-
cal relevance and subject to considerable interobserver
variation.18
• Acute inflammation, characterised by damage to glandular
structures by inflammatory cells or the presence of
leucocytes in the glandular lumina. The extent of acute
inflammation (for example, the number of biopsies
involved) may also be indicated because this information
may explain increased serum PSA values or clinical
findings.
• Chronic granulomatous inflammation, which includes xan-
thogranulomatous inflammation. This condition can cause
greatly raised PSA concentrations and a false positive
digital rectal examination.15
• (Extensive) atrophy, no malignancy. In particular, multiple
biopsies with postatrophic hyperplasia may be reported as
such, although in itself this finding has no clinical
consequence.
• Prostatic intraepithelial neoplasia (PIN). Although initially
low and high grade PIN were distinguished, now only (high
grade) PIN is reported. The histological criteria required for
a diagnosis of (high grade) PIN are described by
Bostwick.9 19 The single most important criterion is the
presence of prominent nucleoli in at least 10% of the
dysplastic luminal cells. The extent and architectural
pattern of PIN may also be reported because some types
(solid, comedo, and cribriform) may be associated with
prostate cancer because they may represent intraductal
spread of high grade cancer.20
• Adenocarcinoma. The location(s) of the foci of adenocarci-
noma should be recorded. In this way, the number of posi-
tive biopsies is implicitly known to the clinician. If a small
focus (< 3 mm) of adenocarcinoma is present in only one
needle biopsy this may be recorded as “focal adenocarci-
noma” in the conclusion, although the clinical relevance of
this term might be limited.3 21 The pathology committee of
the ERSPC recommends an estimation of the proportion of
tumour involvement of the needle biopsies, particularly for
study reasons.22 23 Extensive involvement may discourage
surgical treatment.24 It is common practice to report the
presence of perineural invasion of the adenocarcinoma,
although its clinical impact is controversial.18 23 24
• Suspect for but not diagnostic for adenocarcinoma, if the
lesion is too small and/or lacks sufficient criteria to be able
to make a definite diagnosis of adenocarcinoma.18 No
difference is made between lesions that are probably benign
and those that are probably malignant because this will not
change the follow up policy.25 The pathology committee of
the ERSPC recommends none of the acronyms that have
been proposed recently, such as AAP (atypical acinar prolif-
eration) or ASAP (atypical small acinar proliferation). First,
lesions suspicious for adenocarcinoma do not represent a
separate entity and second, their morphology may vary
from a few single atypical cells to strands of abnormal cells
or glands with atypical features. This diagnosis is followed
by repeat biopsies directed at the site of the initial lesion.
• Other malignancies, including carcinosarcoma, sarcoma,
adenocarcinoma of the colon, etc.
When adenocarcinoma, high grade PIN, or lesions suspect for
adenocarcinoma are present at separate sites, they should also
be reported separately. Table 1 lists the potential clinical con-
sequences of the most common diagnoses.
Diagnostic pitfalls3 include:
• Adenosis, which fortunately is a very rare finding in
peripheral zone derived needle biopsies. Adenosis, which is
338 van der Kwast, Lopes, Santonja, et al
www.jclinpath.com
 on 13 November 2006 jcp.bmj.comDownloaded from 
characterised by a condensation of small glands sur-
rounded by sporadic basal cells, is also known as atypical
adenomatous hyperplasia.26 This last term is not recom-
mended by all members because “atypical” may suggest a
relation with malignancy.
• Postatrophic lobular hyperplasia (frequent).
• Seminal vesicle (frequent).
• Glands of the verumontanum (frequent).
• Nephrogenic adenoma or nephrogenic metaplasia (very
rare).
• Sclerosing adenosis (very rare).
GUIDELINES FOR REPORTING OF PROSTATE
CANCER GRADE
Although several grading systems can be used, it is
recommended that the Gleason score system should be used.
Advantages of this grading system are its general use and the
large amount of data in the literature on its prognostic impact
and accuracy. Furthermore, the Gleason score system is based
on architectural features, which are easy to learn (see website
www.pathology.ks.se/egevad/engGleason.html or http://
www.eur.nl/fgg/pathol/quiz.htm for self-assessment on nee-
dle biopsies). The participation of pathologists in external
quality assurance programmes for prostate cancer grading (if
available) is recommended to reduce interobserver variation.
As advocated by Epstein,27 Gleason scores of 2 to 4 should
not be attributed to prostatic adenocarcinoma on needle biop-
sies. We would recommend that the lowest Gleason growth
pattern that can be assessed in needle biopsies is growth pat-
tern 3, implying that a Gleason score of 6 is the lowest possi-
ble on peripheral zone needle biopsies.
“The pathology committee of the ERSPC recommends
none of the acronyms that have been proposed
recently, such as AAP (atypical acinar proliferation) or
ASAP (atypical small acinar proliferation)”
An important feature of the Gleason system is that it takes
into account the heterogeneity of prostate cancer by including
the two most prominent growth patterns. Thus, in sextant
needle biopsies the Gleason score can range from 6 to 10. The
location of a separate area of high grade (Gleason growth pat-
tern 4 or 5) should always be reported, irrespective of its
extent in the needle biopsy. If, in addition to the predominant
growth pattern 3, both pattern 4 and 5 are present in the nee-
dle biopsies it is suggested that the highest pattern in addition
to the predominant pattern should be included in the Gleason
score (that is, 3 + 5 = 8). This follows the guidelines of the
American College of Pathologists.28
QUALITY CONTROL
The standardisation of processing and reporting on prostate
needle biopsies to avoid medicolegal complications will
become increasingly important. It is recommended that
pathologists responsible for reporting on prostatic needle
biopsies participate in an external quality assurance pro-
gramme to reduce interobserver variation in diagnosis and
Gleason score grading.
As a measure of quality control, the average length of nee-
dle biopsies and the percentage of inadequate biopsies can be
used. The frequency of suspect lesions should give an indica-
tion as to the degree of confidence reached by the pathologist.
This is of course related to several factors, including the popu-
lation under study, the quality of needle biopsies and their
processing, in addition to the staining and the confidence of
the pathologist. For instance, in the setting of prostate cancer
screening, the percentage of suspect lesions should not rise
above 5% because this will lead to a too frequent indication of
repeat biopsies.
. . . . . . . . . . . . . . . . . . . . .
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Table 1 Prostatic needle biopsy diagnosis and clinical relevance in early detection programme (The Rotterdam
algorithm22)
Diagnosis Consequence
Inadequate material Repeat sextant biopsies within 1 year
Benign Rescreening at the regular intervals
Inflammation, either acute or granulomatous Rescreening at the regular intervals
Isolated high grade PIN, no cancer, no lesion suspect for cancer Repeat sextant needle biopsies within 6 months
Lesion suspect for cancer, no definite cancer Additional biopsies from region suspected of carcinoma within 6 weeks
Definite adenocarcinoma Referal to clinician/treatment
Other malignancy Referal to clinician/treatment
PIN, prostatic intraepithelial neoplasia.
Take home messages
• The urological work up and the biopsy procedure should be
performed by a limited number of experienced specialists in
each screening centre and in each centre an experienced
“reference pathologist” should review suspicious cases
• With regard to tissue processing, ideally each biopsy core
should be embedded separately (at minimum, biopsies
from either side of the prostate should be embedded sepa-
rately), biopsies should be flat embedded and sections of
the core should be taken at two levels
• The nomenclature of prostatic lesions in pathology reports
should be uniform and the following terms are recom-
mended: benign, no abnormality; acute inflammation;
chronic granulomatous inflammation, atrophy, no malig-
nancy; prostatic intraepithelial neoplasia (with the extent
and architectural pattern being reported); adenocarcinoma
(with the locations of the foci being recorded); suspect for
but not diagnostic for adenocarcinoma; and other
malignancies
• The Gleason score system should be used because of its
general use and its prognostic power
• As a measure of quality control, the average length of nee-
dle biopsies and the percentage of inadequate biopsies
can be used
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